Find, compare & contact
Diloxanide furoate
API Manufacturers & Suppliers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Diloxanide furoate API 3736-81-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Diloxanide furoate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Diloxanide furoate
- Synonyms:
- 2,2-dichloroacetamido-4-n-methylphenyl 2-furoate , 4-(n-methyl-2,2-dichloroacetamido)phenyl 2-furoate , Dichlofurazol , Diloxanidi furoas
- Cas Number:
- 3736-81-0
- DrugBank number:
- DB14638
- Unique Ingredient Identifier:
- YP4N72IW34
General Description:
Diloxanide furoate is a chemical compound identified by the CAS number 3736-81-0. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica. Diloxanide may also be used concurrently, or sequentially, with other agents such as the nitroimidazoles (eg. metronidazole) in the treatment of invasive or extraintestinal forms of amebiasis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Diloxanide furoate undergoes metabolic processing primarily in: Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation (99% of diloxanide occurs as glucuronide and 1% as free diloxanide in the systemic circulation). This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Diloxanide furoate are crucial for its therapeutic efficacy: Bioavailability is 90% (in diloxanide parental form), however diloxanide furoate is slowly absorbed from the gastrointestinal tract. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Diloxanide furoate is an important consideration for its dosing schedule: 3 hours. This determines the duration of action and helps in formulating effective dosing regimens.
Route of Elimination:
The elimination of Diloxanide furoate from the body primarily occurs through: Renal (90%, rapidly excreted as glucuronide metabolite). 10% is excreted in the feces as diloxanide. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Pharmacodynamics:
Diloxanide furoate exerts its therapeutic effects through: Diloxanide is a luminal amebicide, however the mechanism of action of diloxanide is unknown. Diloxanide destroys the trophozoites of E. histolytica that eventually form into cysts. The cysts are then excreted by persons infected with asymptomatic amebiasis. Diloxanide furoate is a prodrug, and is hydrolyzed in the gastrointestinal tract to produce diloxanide, the active ingredient. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Diloxanide furoate functions by: Unknown. Diloxanide may inhibit protein synthesis. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Diloxanide furoate belongs to the class of organic compounds known as phenol esters. These are aromatic compounds containing a benzene ring substituted by a hydroxyl group and an ester group, classified under the direct parent group Phenol esters. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Phenol esters class, specifically within the None subclass.
Categories:
Diloxanide furoate is categorized under the following therapeutic classes: Amebicides, Anti-Infective Agents, Antiparasitic Agents, Antiprotozoals. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Diloxanide furoate is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Diloxanide furoate manufacturers | traders | suppliers
We have 1 companies offering Diloxanide furoate produced in 1 different countries.
Get in contact with the supplier of your choice:
- SETV Global from India, product country of origin India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
